Last reviewed · How we verify
Beclomethasone (BDP)
Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.
Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone (BDP) |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is an inhaled corticosteroid that reduces airway inflammation by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced recruitment of immune cells, and decreased mucus production. It is commonly used as a maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD) to prevent symptoms and exacerbations.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia / hoarseness
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |